+1 Recommend
1 collections
      • Record: found
      • Abstract: found
      • Article: found

      The Relationship of NT-proBNP and Dialysis Parameters with Outcome of Incident Haemodialysis Patients: Results from the Membrane Permeability Outcome Study

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.


          Background/Aims: The association of raised levels of natriuretic peptides with elevated risk of mortality was investigated in the present analysis of the Membrane Permeability Outcome study. Methods: N-terminal probrain type natriuretic peptide (NT-proBNP) was measured in 618 incident haemodialysis patients, randomised to either high-flux or low-flux. Characteristics of patients with NT-proBNP levels below or above the median were descriptively analysed and survival analysis was performed. Results: Median NT-proBNP value was 2,124 pg/ml, with 1,854 pg/ml in the high-flux and 2,919 pg/ml in the low-flux group. Survival probability was lowest in patients with both a history of cardiovascular disease and NT-proBNP values above the median (p < 0.001). A multivariate Cox proportional hazard model showed interaction between presence of cardiovascular diseases and NT-proBNP levels above the median. Conclusions: NT-proBNP is an independent predictor of mortality also in incident haemodialysis patients. Lower concentrations associated with high-flux dialysis suggest a possible biological link to improved survival in this group.

          Related collections

          Most cited references 16

          • Record: found
          • Abstract: not found
          • Article: not found

          Natriuretic peptides.

            • Record: found
            • Abstract: found
            • Article: not found

            B-type natriuretic peptide in cardiovascular disease.

            Natriuretic peptide hormones, a family of vasoactive peptides with many favourable physiological properties, have emerged as important candidates for development of diagnostic tools and therapeutic agents in cardiovascular disease. The rapid incorporation into clinical practice of bioassays to measure natriuretic peptide concentrations, and drugs that augment the biological actions of this system, show the potential for translational research to improve patient care. Here, we focus on the physiology of the natriuretic peptide system, measurement of circulating concentrations of B-type natriuretic peptide (BNP) and the N-terminal fragment of its prohormone (N-terminal BNP) to diagnose heart failure and left ventricular dysfunction, measurement of BNP and N-terminal BNP to assess prognosis in patients with cardiac abnormalities, and use of recombinant human BNP (nesiritide) and vasopeptidase inhibitors to treat heart failure.
              • Record: found
              • Abstract: found
              • Article: not found

              Plasma brain natriuretic peptide concentration: impact of age and gender.

              We wished to examine the effects of age and gender on plasma brain natriuretic peptide (BNP) concentration in a population-based study. Measurement of BNP concentration is approved for use in the diagnosis of heart failure and may aid in the detection of left ventricular dysfunction. Although BNP is approved for clinical use, there are few data regarding the range of BNP observed in persons without cardiovascular disease or cardiac dysfunction. These data are essential for the interpretation of BNP. In 2,042 randomly selected residents of Olmsted County, Minnesota, >44 years old, BNP (Shionogi and Biosite assays), Doppler echocardiography, and medical record review were performed. A normal subset of subjects (n = 767) in sinus rhythm without cardiovascular, renal, or pulmonary disease or diabetes; on no cardiovascular medications; and with normal systolic, diastolic, and valvular function was identified. Within the normal subset, the distribution of BNP differed by age, gender, and assay system. With both assays, BNP increased significantly with age and was significantly higher in women than men, leading to age-, gender-, and assay-specific reference ranges. Receiver operating characteristic analysis for the ability of BNP to detect an ejection fraction < or = 40% was performed in each age/gender stratum in the entire cohort (n = 2,042) and confirmed that discriminatory values for BNP for detection of reduced ejection fraction were higher in women and older persons and were different between the two assays. Interpretation of BNP should include consideration of age-, gender-, and assay-specific partition values.

                Author and article information

                Blood Purif
                Blood Purification
                S. Karger AG
                June 2013
                28 March 2013
                : 35
                : 1-3
                : 216-223
                aDepartment of Nephrology, Dialysis and Renal Transplantation, A. Manzoni Hospital, Lecco, Italy; bDepartment of Nephrology, University Hospital, Strasbourg, France; cDepartment of Nephrology, University Hospital Reina Sofia, Cordoba, Spain; dDepartment of Nephrology, Danderyd University Hospital, Karolinska Institute, Stockholm, Sweden; eDepartment of Internal Medicine, Nephrology Section, University Hospital, Ghent, Belgium; fDepartment of Nephrology and Intensive Care, St. Bortolo Hospital, Vicenza, Italy; gDepartment of Nephrology, Hospital Gregorio Marañon, Madrid, Spain; hDepartment of Nephrology, Dialysis and Renal Transplantation, S. Orsola-Malpighi Hospital, Bologna, Italy; iDepartment of Nephrology, University Hospital Reims, Reims, France; jDepartment of Nephrology and Transplantation Medicine, Wroclaw Medical University, Wroclaw, Poland; kClinical Research, Fresenius Medical Care, Bad Homburg, Germany
                Author notes
                *Prof. Francesco Locatelli, Department of Nephrology, Dialysis and Renal Transplantation, Alessandro Manzoni Hospital, Via dell'Eremo 9/11, IT-23900 Lecco (Italy), E-Mail f.locatelli@ospedale.lecco.it
                347076 Blood Purif 2013;35:216-223
                © 2013 S. Karger AG, Basel

                Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

                Page count
                Figures: 1, Tables: 1, Pages: 8
                Original Paper


                Comment on this article